Beijing Yipuan Bio-Medical Technology

Beijing Yipuan Bio-Medical Technology is a Chinese biotechnology company focused on the development of innovative therapies for metabolic diseases, including type 2 diabetes and obesity. The company specializes in the design and optimization of multi-target agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors. Their lead programs aim to provide more effective and convenient treatment options for patients with metabolic syndrome and related conditions like NASH. Yipuan Bio leverages its expertise in peptide and small molecule chemistry to advance a pipeline of next-generation metabolic regulators through clinical development.